Clinical trials: Multi-food Allergy
Food Allergy
Multi Immunotherapy to Test Tolerance and Xolair
This is a phase 2 randomized, double-blind, placebo controlled study which will be conducted at multiple centers in the U.S. All subjects will receive oral immunotherapy for their specific food allergies (limited to 5 of those…
- Trial name
- M-TAX (NCT02626611)
- Testing
- Omalizumab, Food Flour Buildup
- Where
- 7 sites in United States
- Volunteers
- 70 people
- Sponsor
- Kari Christine Nadeau
Atopic Dermatitis
A Study of Orally Administered IPG7236 in Healthy Adult Participants
The study is a phase 1, randomized, double-blind, placebo-controlled, single and multiple dose escalation study to evaluate the safety, tolerability, pharmacokinetic and food effect of orally administered IPG7236 in healthy adult…
- Trial name
- NCT05288543
- Testing
- IPG7236- Single ascending dose, IPG7236- Multiple ascending dose
- Where
- Australia
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Nanjing Immunophage Biotech Co., Ltd
Infant Development
Acceptability and Tolerance Study of an Amino Acid Formula with HMOs
To evaluate the acceptability (including gastrointestinal tolerance and compliance) of a hypoallergenic amino acid infant formula with HMOs for the dietary management of cows' milk allergy in infants less than 12 months of age.
- Trial name
- NCT04575298
- Testing
- Acceptability, tolerance study for an infant formula with human milk oligosaccharides
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Société des Produits Nestlé (SPN)
Food IgE-mediated Allergy, Immunotherapy
Omalizumab to Accelerate a Symptom-driven Multi-food OIT
This study will determine the dose-related efficacy of a 20-week treatment of omalizumab started 8 weeks before the onset of a symptom-driven multi-food oral immunotherapy (OIT) protocol at decreasing time to OIT maintenance…
- Conditions
- Food IgE-mediated Allergy, Immunotherapy, Omalizumab, Physiological Effects of Drugs
- Trial name
- BOOM (NCT04045301)
- Testing
- Omalizumab 16mg/kg, Omalizumab 8mg/kg, Multi-food oral immunotherapy (OIT)
- Where
- 3 sites in Canada
- Volunteers
- 90 people
- Sponsor
- Philippe Bégin
Food Allergy
Open-label Extension Study of ADP101
This is an open-label, safety extension study for participants who participated in the Harmony study (protocol ADP101-MA-01).
- Trial name
- NCT05243719
- Testing
- ADP101
- Where
- 14 sites in United States
- Volunteers
- 45 people
- Sponsor
- Alladapt Immunotherapeutics, Inc.
Food Allergy
Low Dose Multi-OIT for Food Allergy (LoMo)
Oral immunotherapy (OIT) is a food allergy treatment where small amounts of the food a child is allergic to is eaten and gradually increased over time with the aim to be able to eat a certain amount of the allergen without…
- Trial name
- LoMO (NCT03799328)
- Testing
- multi-OIT
- Where
- Canada
- Volunteers
- 18 people
- Sponsor
- The Hospital for Sick Children
Pulmonary Disease, Tuberculosis, Pulmonary
Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults
A Phase 1, Partially Blind, Placebo Controlled, Randomized, Combined Single Ascending Dose (SAD) with a Food Effect Cohort (Part 1), Multiple Ascending Dose (MAD) (Part 2), and Relative Bioavailability (rBA) (Part 3) Study to…
- Conditions
- Pulmonary Disease, Tuberculosis, Pulmonary, Tuberculosis, Multi Drug Resistant Tuberculosis
- Trial name
- NCT04493671
- Testing
- TBAJ-876 suspension, TBAJ-876 100 mg tablet, TBAJ-876 25 mg tablet
- Where
- United States
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- Global Alliance for TB Drug Development
Healthy Study Participants, Chronic Spontaneous Urticaria
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UCB8600 in Healthy Participants, Atopic Participants, and Chronic Spontaneous Urticaria Participants
The purpose of the study is to assess safety, tolerability and pharmacokinetics (PK) of oral UCB8600.
- Trial name
- NCT04444466
- Testing
- UCB8600
- Where
- Bulgaria
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- UCB Biopharma SRL
Food Hypersensitivity, Probiotic
Colonization and Persistence Capacity of a Multi-strain Probiotics in Pediatric Food Allergy to Milk or Egg.
This study evaluates the addition of three probiotics (Bifidobacterium longum, Bifidobacterium breve and Bifidobacterium infantis) in the treatment of pediatric food allergic children to milk or egg.
- Trial name
- NCT03639337
- Testing
- Multi-strain probiotic
- Where
- Italy
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Bambino Gesù Hospital and Research Institute
Food Allergy, Early Allergen Introduction
Food Introduction for Risk Reduction, Support Tolerance: Behavioral Intervention for Toddler Eating Success
The goal of this clinical trial is to evaluate the feasibility, acceptability, perceived safety, and adherence outcomes of FIRST BITES (Food Introduction for Risk Reduction, Support Tolerance: Behavioral Intervention for Toddler…
- Trial name
- FIRST BITES (NCT07857057)
- Testing
- Education and Reminders/Supportive Communication, Education
- Where
- 3 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Healthy Volunteers, Atopic Diathesis and Atopic Dermatitis
Single Dose and Multiple Dose Study to Assess Safety and Tolerability of LOU064
This is a 6-part first-in-human study in up to approximately 184 participants. Parts 1 to 5 is in health volunteers and part 6 is in subjects with atopic dermatitis.
- Trial name
- NCT03918980
- Testing
- LOU064
- Where
- 2 sites in Germany, Netherlands
- Volunteers
- 185 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Atopic Dermatitis, Hidradenitis Suppurativa (HS)
A Phase I Study of QLS12010 Capsules: Safety, Tolerability, PK, PD, and Food Effects in Healthy Adults and Moderate to Severe Atopic Dermatitis Patients
The goal of this clinical trial is to evaluate the safety, tolerability, PK, and PD of single and multiple ascending doses of QLS12010 Capsules and the effect of food on their PK profiles in healthy adult participants and…
- Conditions
- Atopic Dermatitis, Hidradenitis Suppurativa (HS), Rheumatoid Arthritis (RA)
- Trial name
- NCT06946641
- Testing
- QLS12010
- Where
- China
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Shanghai Qilu Pharmaceutical Research and Development Center LTD
Immune System Diseases
Omalizumab With Oral Food Immunotherapy With Food Allergies Open Label Safety Study in a Single Center
The long-term goal of the investigators study is to develop a better and safer treatment for, and to potentially cure patients with single or multiple food allergies.
- Trial name
- NCT01510626
- Testing
- Food proteins, Omalizumab
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Stanford University
Food Allergy
Multi OIT to Test Immune Markers After Minimum Maintenance Dose
Few studies have been conducted to optimize safety of multiple food allergen oral immunotherapy (OIT) in conjunction with Omalizumab as well as to identify the immunological mechanism(s) underlying any long-lasting effects of…
- Trial name
- NCT03181009
- Testing
- Omalizumab, Food Flour Allergens
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Andrew Long, PharmD
Allergy, Nut
Low Dose Multi-Nut Oral Immunotherapy in Pre-schoolers With a Multi-Nut Allergy
The LMNOP trial will be a 2-armed, open-label, randomised controlled trial (RCT), 2:1. Over a period of 18 months, children in the Multi-Nut Oral Immunotherapy Treatment (OIT) Group (experimental arm) will undergo low dose OIT to…
- Trial name
- LMNOP (NCT05049512)
- Testing
- Multi-nut OIT
- Where
- Australia
- Volunteers
- 12 people
- Sponsor
- Murdoch Childrens Research Institute
Seasonal Allergic Rhinitis
A Single and Multiple Dose Study to Explore the Safety of JNJ-38224342 in Healthy Patients and Patients With Seasonal Allergies
A single and multiple dose study to assess the safety of JNJ 38224342 compared to placebo in healthy volunteers and in volunteers with seasonal allergies.
- Trial name
- NCT01054352
- Testing
- JNJ38224342
- Where
- Canada
- Volunteers
- 182 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Food Allergy
E-B-FAHF-2, Multi OIT and Xolair for Food Allergy
The purpose of this study is testing the use of Enhanced-Butanol purified-Food Allergy Herbal Formula-2 (E-B-FAHF-2) Chinese herbal therapy in combination with multi-food oral immunotherapy (OIT) and Xolair® (Omalizumab) to help…
- Trial name
- FAHF-2 (NCT06103656)
- Testing
- Drug: Chinese Herbal Medication, Drug: Omalizumab
- Volunteers
- 33 people
- Sponsor
- New York Medical College
Allergy;Food
Biomarkers in Food Allergy Diagnosis
Food allergy is a global burden, affecting patients, society as a whole and the economy. For most common food allergies, patients synthesize specific IgE-antibodies against harmless food proteins.
- Trial name
- APSIS (NCT04604912)
- Where
- 2 sites in Luxembourg
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Luxembourg Institute of Health
Eosinophilic Esophagitis (EoE)
SAD, MAD and Food Effect Evaluation of Safety, Tolerability, and PK of AQ280 in Healthy Subjects
The principal aim of this study is to obtain safety and tolerability data when AQ280 is administered orally as single and multiple doses to healthy subjects.
- Trial name
- NCT05485779
- Testing
- AQ280
- Where
- United Kingdom
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- AQILION AB
Peanut Allergy, Multi-food Allergy
Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants
This study is a multi-center, randomized, double-blind, placebo-controlled study in participants 1 to less than 56 years of age who are allergic to peanut and at least two other foods (including milk, egg, wheat, cashew…
- Trial name
- OUtMATCH (NCT03881696)
- Testing
- Omalizumab, Multi-Allergen Oral Immunotherapy
- Where
- 10 sites in United States
- Volunteers
- 458 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)